In­cyte's stock sinks as piv­otal skin dis­ease da­ta dis­ap­point

In­cyte’s topline piv­otal da­ta for its oral ther­a­py for a painful in­flam­ma­to­ry skin con­di­tion ap­pear some­what dis­ap­point­ing, with ef­fi­ca­cy falling short of an­a­lysts’ ex­pec­ta­tions and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER